Composition for treatment of joint disease and method thereof

Abstract

The present invention provides a pharmaceutical composition comprising mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for the treatment of the joint disease. The mesenchymal stem cells in the composition are at least one selected from the group consisting of infra-patellar fat pad stromal cells, bone marrow stem cells, Wharton's jelly stem cells and adipose derived stem cells. The concentration of the hyaluronan is in a range from 25% (v/v) to 75% (v/v). The present invention further provides a method for treating a joint disease, comprising a step of administrating a composition containing mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier to an injured joint tissue of a subject.

1 - 18 . (canceled) 
     
     
         19 . A pharmaceutical composition comprising mesenchymal stem cells, a hyaluronan, and a pharmaceutically acceptable carrier, wherein the mesenchymal stem cells are at least one selected from the group consisting of infra-patellar fat pad stromal cells and Wharton's jelly stem cells, and wherein the hyaluronan has a molecular weight of between 5000 and 10000 KDa and a concentration in a range of from 2.5 mg/mL to 7.5 mg/mL. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the concentration of the hyaluronan is in a range of from 2.5 mg/mL to 5.0 mg/mL. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein the concentration of the hyaluronan is about 2.5 mg/mL. 
     
     
         22 . The pharmaceutical composition of  claim 19 , wherein the mesenchymal stem cells are cultured to passage 3 to passage 6. 
     
     
         23 . The pharmaceutical composition of  claim 19 , wherein the mesenchymal stem cells are in an amount of from 1.6×10 7  to 1×10 9  cells. 
     
     
         24 . The pharmaceutical composition of  claim 19 , wherein the mesenchymal stem cells are infra-patellar fat pad stromal cells. 
     
     
         25 . The pharmaceutical composition of  claim 19 , wherein the mesenchymal stem cells are Wharton's jelly stem cells. 
     
     
         26 . A method for treating a joint disease, comprising administrating an effective amount of the pharmaceutical composition of  claim 19  to an injured joint tissue of a subject in need thereof. 
     
     
         27 . The method of  claim 26 , wherein the concentration of the hyaluronan is in a range of from 2.5 mg/mL to 5.0 mg/mL. 
     
     
         28 . The method of  claim 27 , wherein the concentration of the hyaluronan is about 2.5 mg/mL. 
     
     
         29 . The method of  claim 26 , wherein the pharmaceutical composition is administered to the subject by injection. 
     
     
         30 . The method of  claim 26 , wherein the joint disease is articular cartilage defect, chronic articular rheumatism, arthritis deformans, or periarthritis humeroscapularis. 
     
     
         31 . The method of  claim 26 , wherein the mesenchymal stem cells are cultured to passage 3 to passage 6. 
     
     
         32 . The method of  claim 26 , wherein the pharmaceutical composition comprises the mesenchymal stem cells in an amount of 1.6×10 7  to 1×10 9  cells. 
     
     
         33 . The method of  claim 26 , wherein the mesenchymal stem cells are infra-patellar fat pad stromal cells. 
     
     
         34 . The method of  claim 26 , wherein the mesenchymal stem cells are Wharton's jelly stem cells.